ClinicalTrials.gg
TerminatedNCT00040391Updated Dec 1, 2016

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

A Phase 2 interventional study of Investigational drug and Irinotecan in Colorectal Neoplasms and Diarrhea, sponsored by Celgene Corporation. Terminated at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-01.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 200 studies testing irinotecan in Colorectal Neoplasms — 25 open to participants now, 32 under way, 6 of them phase 3. Irinotecan · Colorectal Neoplasms.

Started
2002
with 6 others
Phase 2
117 of 200
16 open now
Registered
32nd of 200
by date

Among the 200 studies testing irinotecan in Colorectal Neoplasms, this one is one of 7 that started in 2002, is one of 117 in phase 2, and was the 32nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

25 of the 200 studies testing irinotecan in Colorectal Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies testing irinotecan in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The study will combine a new investigational drug with standard anti-cancer drugs for the treatment of advanced colorectal cancer. The standard and approved treatment for colorectal cancer is to undergo chemotherapy with a combination of irinotecan (also known as CPT-11, Camptosar), 5-fluorouracil (also known as 5-FU), and leucovorin (also known as LV). This is known as the triple therapy. One of the major side effects of CPT-11/5-FU/LV chemotherapy treatment is diarrhea. The purpose of this research study is to see whether adding this investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. This study will also determine if adding the investigational drug to triple therapy has a positive effect on tumors.

03

Conditions studied

  • Colorectal Neoplasms
  • Diarrhea

Keywords

  • Pharmacia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion criteria

Inclusion Criteria:

  • Age 18 years or older
  • Diagnosis of colorectal cancer or adenocarcinoma of the appendix
  • A tumor mass that can be measured
  • Resolution of all toxic effects of any radiotherapy or surgical procedures to NCI CTC grade less than or equal to 1
  • Willingness and ability to comply with scheduled visits, treatment plan, and laboratory tests, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • Women that are pregnant or lactating
  • Prior treatment with Irinotecan
  • Partial or complete bowel obstruction, known chronic malabsorption, or total colectomy or other major abdominal surgery that might result in substantial alteration in transit or absorption of oral medication
  • Administration of the last dose of any previous therapy for colorectal cancer within 6 months previous to randomization
  • Current enrollment in another clinical trial
  • Administration of any prior systemic anticancer therapy for colorectal cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
06

Study locations

28 sites
  • Research Center
    Little Rock, Arkansas 72205, United States
  • Research Center
    Anaheim, California 92801, United States
  • Research Center
    Concord, California 94520, United States
  • Research Center
    Gilroy, California 95020, United States
  • Research Center
    Los Angeles, California 90057, United States
  • Research Center
    Jacksonville, Florida 32207, United States
  • Research Center
    New Port Richey, Florida 34652, United States
  • Research Center
    New Orleans, Louisiana 70115, United States
  • Research Center
    Scarborough, Maine 04074-9308, United States
  • Research Center
    Pittsfield, Massachusetts 01201, United States
  • Research Center
    East Lansing, Michigan 48824, United States
  • Research Center
    St. Joseph, Michigan 49085, United States
  • Research Center
    Minneapolis, Minnesota 55455, United States
  • Research Center
    St. Joseph, Missouri 64507, United States
  • Research Center
    Las Vegas, Nevada 89106, United States
  • Research Center
    East Setauket, New York 11733, United States
  • Research Center
    Northport, New York 11768-2364, United States
  • Research Center
    Burlington, North Carolina 27216, United States
  • Research Center
    Greenville, North Carolina 27834, United States
  • Research Center
    Zanesville, Ohio 43701, United States
  • Research Center
    Lancaster, Pennsylvania 17605, United States
  • Research Center
    Philadelphia, Pennsylvania 19140-5189, United States
  • Research Center
    Charleston, South Carolina 29403, United States
  • Research Center
    Charleston, South Carolina 29406, United States
  • Research Center
    Germantown, Tennessee 38138, United States
  • Research Center
    Dallas, Texas 75230, United States
  • Research Center
    Madison, Wisconsin 53792-2454, United States
  • Research Center
    Milwaukee, Wisconsin 53215, United States
07

References and documents

Publications

  • Pan CX, Loehrer P, Seitz D, Helft P, Juliar B, Ansari R, Pletcher W, Vinson J, Cheng L, Sweeney C. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology. 2005;69(1):63-70. doi: 10.1159/000087302. Epub 2005 Aug 2. PubMed 16088234 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00040391
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jun 27, 2002
Start date
Jun 2002
Last update
Dec 1, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Drugs, Investigational · Irinotecan · Leucovorin

Start the discussion